| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1007910170 |
| P356 | DOI | 10.1186/BCR3637 |
| P8608 | Fatcat ID | release_ti6jxvedvvewnhne7wu5jw2rmq |
| P932 | PMC publication ID | 4053225 |
| P698 | PubMed publication ID | 24693969 |
| P5875 | ResearchGate publication ID | 261325506 |
| P2093 | author name string | Ningyan Zhang | |
| Zhiqiang An | |||
| Yun Shi | |||
| Weixu Meng | |||
| Hui Deng | |||
| Xuejun Fan | |||
| P2860 | cites work | Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 | Q24321567 |
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. | Q27824819 | ||
| Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling | Q27851446 | ||
| Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 | ||
| Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells | Q28201813 | ||
| Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy | Q28235277 | ||
| Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. | Q54076350 | ||
| HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. | Q54600558 | ||
| Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 | Q62604209 | ||
| Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu | Q73453082 | ||
| Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells | Q77948519 | ||
| Trastuzumab--mechanism of action and use in clinical practice | Q29615810 | ||
| Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin | Q30839490 | ||
| Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group | Q33730978 | ||
| Neoadjuvant trastuzumab induces apoptosis in primary breast cancers | Q34394358 | ||
| Targeting the function of the HER2 oncogene in human cancer therapeutics | Q34766486 | ||
| Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? | Q36613598 | ||
| Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy | Q36645388 | ||
| Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. | Q36710542 | ||
| A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy | Q36924491 | ||
| Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodies | Q37106206 | ||
| Association with membrane protrusions makes ErbB2 an internalization-resistant receptor | Q38345553 | ||
| Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. | Q39559611 | ||
| Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma | Q40401124 | ||
| A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies | Q40552147 | ||
| Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes | Q40568569 | ||
| Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. | Q40798689 | ||
| Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. | Q40864655 | ||
| TGFalpha expression impairs Trastuzumab-induced HER2 downregulation | Q45286133 | ||
| Suppressing HER2/neu-mediated cell transformation by transcriptional repressors | Q45881046 | ||
| Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid | Q46834254 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | R33 | |
| P577 | publication date | 2014-04-02 | |
| P1433 | published in | Breast Cancer Research | Q2208481 |
| P1476 | title | Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation | |
| P478 | volume | 16 |
| Q55026505 | A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. |
| Q55026796 | A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. |
| Q41682527 | Crk II silencing down-regulates IGF-IR and inhibits migration and invasion of prostate cancer cells |
| Q59123161 | EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis |
| Q57072196 | Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer |
| Q30391848 | Efficient generation of monoclonal antibodies from single rhesus macaque antibody secreting cells. |
| Q48742034 | Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency. |
| Q49486649 | Ex vivo culture of tumor cells from N-methyl-N-nitrosourea-induced bladder cancer in rats: Development of organoids and an immortalized cell line |
| Q55385806 | Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice. |
| Q92132838 | Modeling Basins of Attraction for Breast Cancer Using Hopfield Networks |
| Q42320213 | Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer. |
| Q66679798 | Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes |
| Q58607138 | Receptor Tyrosine Kinase-Targeted Cancer Therapy |
| Q38896842 | Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages |
| Q54979386 | Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion. |
| Q36821168 | Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNγ secretion. |
Search more.